NTRANatera Inc
$266.30
$4.55
(1.73%)
Closed $267.18
$0.88
(0.33%)
After Hours
EarningsAug 6
Mkt Cap$37.61B
Vol994,675.00
Finalized MolDx LCD Includes Expanded Coverage for Nateras Prospera Portfolio
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.The LCD strengthens coverage for Prospera in the surveillance settings...
Business Wire
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
Zacks
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Zacks
Natera Announces IVDR Certification for Signatera Across Multiple Cancers
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a Class C device under the European Unions In Vitro Diagnostic Regulation (IVDR). The IVDR represents one of the worlds most rigorous regulatory...
Business Wire
Signatera MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in JAMA Oncology, evaluating the utility of Signatera, its personalized molecular residual disease (MRD) test, in patients with resected colorectal liver metastases...
Business Wire
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Natera's Aveta partnership brings Signatera into a global Phase 3 head and neck cancer trial to assess MRD and treatment response.
Zacks
Natera Partners With Aveta Biomics On Phase 3 Head And Neck Cancer Trial
(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company, and Aveta Biomics, Inc., an immuno-oncology company, on Monday announced a partnership to support AVTA 30-01, Aveta's Phase 3 trial evaluating its immunotherapy candidate APG-157 in patients with locally advance...
Nasdaq News: Markets
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors, today announced a strategic partnership supporting AVTA 30-01, Avetas global Phase...
Business Wire
U.S. Supreme Court Rejects CareDxA's Appeal in Natera, Inc. (NTRA) False-advertising Dispute
U.S. Supreme Court Rejects CareDxA's Appeal in Natera, Inc. (NTRA) False-advertising Dispute...
Yahoo! Finance: News
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan
Natera's Signatera gains Japan PMDA approval for CRC, marking the country's first approved MRD test and advancing its global expansion.
Zacks
<
1
2
...
>
